RESUMO
The RNA virus, hepatitis E virus (HEV) is the most or second-most important cause of acute clinical hepatitis in adults throughout much of Asia, the Middle East, and Africa. In these regions it is an important cause of acute liver failure, especially in pregnant women who have a mortality rate of 20-30%. Until recently, hepatitis E was rarely identified in industrialized countries, but Hepatitis E now is reported increasingly throughout Western Europe, some Eastern European countries, and Japan. Most of these cases are caused by genotype 3, which is endemic in swine, and these cases are thought to be zoonotically acquired. However, transmission routes are not well understood. HEV that infect humans are divided into nonzoonotic (types 1, 2) and zoonotic (types 3, 4) genotypes. HEV cell culture is inefficient and limited, and thus far HEV has been cultured only in human cell lines. The HEV strain Kernow-C1 (genotype 3) isolated from a chronically infected patient was used to identify human, pig, and deer cell lines permissive for infection. Cross-species infections by genotypes 1 and 3 were studied with this set of cultures. Adaptation of the Kernow-C1 strain to growth in human hepatoma cells selected for a rare virus recombinant that contained an insertion of 174 ribonucleotides (58 amino acids) of a human ribosomal protein gene.
Assuntos
Vírus da Hepatite E/genética , Hepatite E/genética , Mutagênese Insercional , Recombinação Genética , Proteínas Ribossômicas/genética , Animais , Sequência de Bases , Células CACO-2 , Cervos/virologia , Feminino , Genótipo , Hepatite E/mortalidade , Humanos , Masculino , Pessoa de Meia-Idade , Dados de Sequência Molecular , Gravidez , Complicações Infecciosas na Gravidez/genética , Complicações Infecciosas na Gravidez/mortalidade , Especificidade da Espécie , Suínos/virologia , Doenças dos Suínos/genética , Doenças dos Suínos/mortalidadeRESUMO
BACKGROUND: Hepatitis E virus (HEV) infections in immunosuppressed patients can result in chronic hepatitis that rapidly progresses to cirrhosis (1, 2). When immunosuppressed transplant recipients are treated with pegylated -interferon and ribavirin, HEV clears and liver histology improves (2). However, we are not aware of reports about how this therapy works in patients with HIV infection. OBJECTIVE: To describe the clinical and laboratory response to antiviral therapy for chronic HEV infection in a patient also infected with HIV. CASE REPORT: We studied a 48-year-old bisexual male with HIV- 1 infection who was chronically infected with HEV genotype 3a and had several years of painful sensory neuropathy of uncertain cause in the lower limbs (3). He had malaise, persistently abnormal liver function tests, and active inflammation and cirrhosis on liver biopsy (Figure).Before beginning anti-HEV therapy, the patient had an undetectable HIV viral load and a CD4 cell count between 30 and 150 cells/mL for the previous 2 years while receiving combination antiretroviral therapy (abacavirlamivudine once daily and lopinavirritonavir twice daily).
Assuntos
Antivirais/uso terapêutico , Infecções por HIV/imunologia , Hepatite E/tratamento farmacológico , Hospedeiro Imunocomprometido , Interferon-alfa/uso terapêutico , Ribavirina/uso terapêutico , Quimioterapia Combinada , Infecções por HIV/complicações , Hepatite E/complicações , Humanos , Masculino , Pessoa de Meia-IdadeAssuntos
Infecções Oportunistas Relacionadas com a AIDS , Infecções por HIV/complicações , Vírus da Hepatite E/isolamento & purificação , Hepatite E/complicações , Infecções Oportunistas Relacionadas com a AIDS/virologia , Alcoolismo/complicações , Doença Crônica , Infecções por HIV/virologia , Hepatite E/virologia , Humanos , Masculino , Pessoa de Meia-Idade , Carga ViralRESUMO
During the first year of a screening programme in Cornwall, a rural area of southwest England, 5024 young people were screened for genital Chlamydia trachomatis infection. We used mapping software to assess the prevalence of genital chlamydial infection and access to genitourinary medicine services among 16-25 year olds. Using this data, we calculated that attendance at genitourinary medicine clinics in Cornwall varies between 20/1000 and 83/1000 in this age group. Similarly, the rate of positive results varies between 2.9 and 27.4%, depending on place of residence and testing site. The highest rates of infection were noted in two areas with poor access to existing genitourinary medicine clinics. This information can be used to better plan sexual health services.